CRB-602 / Corbus Pharma - LARVOL DELTA

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates (PRNewswire) - "Anti-integrin monoclonal antibodies (mAbs) program targeting the inhibition of TGFβ is progressing on schedule: (i) CRB-601, an anti-αvβ8 mAb, is being developed as a potential treatment for solid tumors. This approach has demonstrated promising data in preclinical cancer models. IND-enabling activities are underway, and the program is progressing toward IND submission in the first half of 2023; (ii) CRB-602 is a discovery stage anti-αvβ6/αvβ8 mAb currently being explored in potential models of cancer and fibrosis."

IND • Pipeline update • Oncology • Solid Tumor

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates (GlobeNewswire) - "CRB-601 is also up to 10x more potent in vitro than its precursor mAb, C6D4...Pre-IND work has commenced, and the program is on schedule for anticipated IND in late 2022; CRB-602 (anti-αvβ6/8 mAb) for fibrotic diseases and cancer....Program is on schedule for an anticipated IND in early 2023."

IND • Oncology • Solid Tumor

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases (GlobeNewswire) - "Corbus Pharmaceuticals Holdings, Inc...announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor β (TGFβ)...Corbus plans to develop CRB-601 for treatment of solid tumors in combination with existing therapies, including checkpoint inhibitors. Phase 1 studies are expected to start in 2022; CRB-602 was developed by Panorama Research Inc. to specifically inhibit both αvβ6 and αvβ8....Phase 1 studies are expected to start in 2022."

Licensing / partnership • New P1 trial • Oncology